TG Therapeutics, Inc. (LON:0VGI)

TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of GBP 3.09 billion. The enterprise value is 3.18 billion.

Market Cap	3.09B
Enterprise Value	3.18B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.20M
Shares Outstanding	n/a
Shares Change (YoY)	+11.64%
Shares Change (QoQ)	-0.96%
Owned by Insiders (%)	4.56%
Owned by Institutions (%)	73.18%
Float	139.47M

Valuation Ratios

The trailing PE ratio is 9.28 and the forward PE ratio is 17.68.

PE Ratio	9.28
Forward PE	17.68
PS Ratio	7.80
PB Ratio	6.84
P/TBV Ratio	6.84
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 41.35, with an EV/FCF ratio of -60.82.

EV / Earnings	9.55
EV / Sales	8.15
EV / EBITDA	41.35
EV / EBIT	42.19
EV / FCF	-60.82

Financial Position

The company has a current ratio of 3.82, with a Debt / Equity ratio of 0.42.

Current Ratio	3.82
Quick Ratio	2.53
Debt / Equity	0.42
Debt / EBITDA	2.43
Debt / FCF	-3.62
Interest Coverage	3.77

Financial Efficiency

Return on equity (ROE) is 111.96% and return on invested capital (ROIC) is 20.37%.

Return on Equity (ROE)	111.96%
Return on Assets (ROA)	7.97%
Return on Invested Capital (ROIC)	20.37%
Return on Capital Employed (ROCE)	11.84%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.06M
Profits Per Employee	890,088
Employee Count	374
Asset Turnover	0.66
Inventory Turnover	0.67

Taxes

Income Tax	-267.61M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.89% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+6.89%
50-Day Moving Average	31.97
200-Day Moving Average	23.92
Relative Strength Index (RSI)	47.77
Average Volume (20 Days)	3,827

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	15.38

Income Statement

In the last 12 months, TG Therapeutics had revenue of GBP 395.70 million and earned 332.89 million in profits. Earnings per share was 2.07.

Revenue	395.70M
Gross Profit	337.69M
Operating Income	76.46M
Pretax Income	65.28M
Net Income	332.89M
EBITDA	76.50M
EBIT	76.46M
Earnings Per Share (EPS)	2.07

Balance Sheet

The company has 97.89 million in cash and 189.36 million in debt, with a net cash position of -91.47 million.

Cash & Cash Equivalents	97.89M
Total Debt	189.36M
Net Cash	-91.47M
Net Cash Per Share	n/a
Equity (Book Value)	451.73M
Book Value Per Share	3.17
Working Capital	329.53M

Cash Flow

In the last 12 months, operating cash flow was -52.13 million and capital expenditures -124,982, giving a free cash flow of -52.26 million.

Operating Cash Flow	-52.13M
Capital Expenditures	-124,982
Free Cash Flow	-52.26M
FCF Per Share	n/a

Margins

Gross margin is 85.34%, with operating and profit margins of 19.32% and 84.13%.

Gross Margin	85.34%
Operating Margin	19.32%
Pretax Margin	16.50%
Profit Margin	84.13%
EBITDA Margin	19.33%
EBIT Margin	19.32%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.64%
Shareholder Yield	-11.64%
Earnings Yield	10.78%
FCF Yield	-1.69%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TG Therapeutics has an Altman Z-Score of 6.79 and a Piotroski F-Score of 3.

Altman Z-Score	6.79
Piotroski F-Score	3